5/1/2025
Last update
5/1/2025
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.8
USERS' SCORE
Good
Based on 1 Review
8.3
Supplement Facts
Serving Size: 2 Caplets
Amount Per Serving
%DV
Calories
10
Total Carbohydrate
2 g
1%¹
Dietary Fiber
1 g
4%¹
Selenium (from culture media)
100 mcg
182%
RM-10 Fermented Organic Mushroom BlendMaitake (Grifola frondosa) mycelia*, Shiitake (Lentinula edodes) mycelia*, Reishi (Ganoderma lucidum) mycelia*, Coriolus versicolor mycelia*, Bionectria ochroleuca mycelia, Wolfiporia cocos mycelia*, Hericium erinaceus mycelia*, Formitopsis cajanderi mycelia*, Annulohypoxylon stygium mycelia*, Agaricus blazei mycelia*
1.16 g
+
Cat's Claw (Uncaria tomentosa) Bark
240 mg
+
Top Medical Research Studies
9
We set out to explore the effects of selenium-containing compounds on breast cancer cells, particularly focusing on their potential as treatments. Our research involved testing several novel selenoesters on two breast cancer cell lines, MCF-7 and MDA-MB-231, to understand how these compounds can impact cell growth and survival.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
Read More
9
We investigated how a fungal polysaccharide extracted from maitake mushrooms can impact breast cancer. This treatment approach focuses on myeloid-derived suppressor cells, or MDSCs, which are known to help tumors grow by suppressing the immune response in cancer patients.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Read More
9
We investigated the potential benefits of D-Fraction, a compound derived from the maitake mushroom, specifically on triple-negative breast cancer (TNBC) cells. TNBC is a challenging subtype of breast cancer with limited treatment options and a high risk of recurrence and metastasis, underscoring the need for innovative therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
Read More
Most Useful Reviews
6
Boost immune system
55 people found this helpful
RM-10 is invaluable for those with serious health issues like cancer or MS. For someone with stage 3 or 4 breast cancer, I recommend taking 10 to 20 pills three times daily to bolster the immune system against cancer and chemotherapy. Following an alkaline diet and consuming RM-10, I am now five years in remission. It’s crucial to stay healthy with the right combination of diet, RM-10, and probiotics.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.8
- All Researches
9
Anticancer effects of selenium compounds
We focused on exploring the effectiveness of organoselenocyanates—specifically derivatives of selenium—on triple-negative breast cancer cells. By designing two series of these compounds incorporating unique chemical structures, we aimed to see how they could impact cancer cell growth and behavior.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Through a careful multi-step synthesis process, we successfully created these selenium compounds and put them to the test against cancer cells. After evaluating their anti-proliferative effects, we discovered that one particular compound, known as 15 a, stood out for its promising results. This compound not only hindered cancer cell migration but also triggered significant changes in the cell cycle, causing cells to halt in the G1 phase and promoting early apoptosis, or programmed cell death.
We further investigated how this compound affected the redox balance within the breast cancer cells. Our findings revealed that 15 a demonstrated antioxidant properties by reducing levels of reactive oxygen species (ROS) and increasing the expression of a protective enzyme called TrxR1. On a molecular level, it also activated pathways related to cell signaling that suppressed cancer cell proliferation by manipulating important proteins such as p-ERK, p-Akt, and c-Myc.
These encouraging results highlight the potential of selenium-based treatments as new therapeutic options for battling triple-negative breast cancer. We believe our insights could pave the way for future developments in cancer therapies.
Read More
9
We investigated the effects of selenium nanoparticles (SeNPs) produced by marine yeast on breast cancer cells, specifically the MCF-7 cell line. Through a detailed process of isolating and identifying the potent yeast strains, we found optimal conditions for generating SeNPs, including specific temperature and pH levels. This biosynthesized form of selenium was then characterized using various techniques for its size and shape.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
When we examined the impact of these nanoparticles on MCF-7 cells, the results were promising. SeNPs displayed significant anti-cancer properties, yielding lower concentrations needed to inhibit cell growth compared to other cancer types like colon and liver cells. In fact, the concentration required to inhibit the growth of MCF-7 cells was as low as 19.59 µg/ml, while it was higher for other cancer cells. Importantly, there were no adverse effects seen on normal human skin fibroblast (HSF) cells, indicating a level of selectivity that could be beneficial in treatment.
Our findings highlighted that treatment with SeNPs led to a halt in cell cycle progression at the G2/M phase and promoted programmed cell death, or apoptosis, in the MCF-7 cells. We also observed increased oxidative stress levels and a decline in the activity of antioxidant enzymes, which suggests a mechanism through which selenium may exert its effects. In conclusion, the biosynthesized selenium nanoparticles from yeast offer promising insights into potential therapies for breast cancer.
Read More
9
Selenium compounds may combat resistance
We focused on how selenium compounds could help fight breast cancer, particularly when it comes to overcoming multidrug resistance, a major hurdle in effective treatment. Our research specifically assessed two novel selenoesters, EDAG-1 and EDAG-8, for their potential to inhibit resistance proteins in breast cancer cells.
Through various analyses, we discovered that these compounds, especially EDAG-8, effectively blocked the action of important efflux pumps known as BCRP, MDR1, and MRP1. This action makes cancer cells more susceptible to treatment, giving us a hopeful avenue for developing better therapies. Notably, the testing showed that EDAG-8 outperformed traditional reference compounds, indicating its promising role in treatment strategies.
Our in silico studies further supported these findings, highlighting that EDAG-8's unique structure and lower binding energy to these proteins enhances its anticancer activity. This reveals a compelling potential for selenium-based treatments in the battle against breast cancer, positioning EDAG-8 as an exciting candidate for future drug development.
Through various analyses, we discovered that these compounds, especially EDAG-8, effectively blocked the action of important efflux pumps known as BCRP, MDR1, and MRP1. This action makes cancer cells more susceptible to treatment, giving us a hopeful avenue for developing better therapies. Notably, the testing showed that EDAG-8 outperformed traditional reference compounds, indicating its promising role in treatment strategies.
Our in silico studies further supported these findings, highlighting that EDAG-8's unique structure and lower binding energy to these proteins enhances its anticancer activity. This reveals a compelling potential for selenium-based treatments in the battle against breast cancer, positioning EDAG-8 as an exciting candidate for future drug development.
Read More
9
We explored the potential of selenium nanoparticles (SeNPs) in treating breast cancer, especially their effects in combination with a KRAS nanovaccine. Our study utilized various stabilizing agents to develop stable SeNPs, with a focus on bovine serum albumin (BSA). The BSA-stabilized SeNPs were particularly noteworthy, showing remarkable stability under different conditions while remaining effective in targeting cancer cells.
When we tested these nanoparticles, we found that they exhibited enhanced toxicity against cancer cell lines, while not harming normal human cells. This selectivity is promising for cancer treatments. Moreover, we observed significant synergy when we combined BSA-SeNPs with the nanovaccine, leading to substantial reductions in tumor size in a mouse model of breast cancer.
Overall, our findings suggest that selenium nanoparticles, especially when paired with immunotherapy approaches like the nanovaccine, could be a valuable strategy inbreast cancer treatment. This innovative combination offers exciting possibilities for improving cancer immunotherapy outcomes.
When we tested these nanoparticles, we found that they exhibited enhanced toxicity against cancer cell lines, while not harming normal human cells. This selectivity is promising for cancer treatments. Moreover, we observed significant synergy when we combined BSA-SeNPs with the nanovaccine, leading to substantial reductions in tumor size in a mouse model of breast cancer.
Overall, our findings suggest that selenium nanoparticles, especially when paired with immunotherapy approaches like the nanovaccine, could be a valuable strategy inbreast cancer treatment. This innovative combination offers exciting possibilities for improving cancer immunotherapy outcomes.
Read More
9
We set out to explore the effects of selenium-containing compounds on breast cancer cells, particularly focusing on their potential as treatments. Our research involved testing several novel selenoesters on two breast cancer cell lines, MCF-7 and MDA-MB-231, to understand how these compounds can impact cell growth and survival.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
What we found was quite promising. The selenoesters showed significant cytotoxic effects, meaning they can kill cancer cells effectively, even at very low doses. We observed that these compounds triggered important processes that lead to cell death, specifically by activating pathways that make cells undergo apoptosis, or programmed cell death.
The mechanisms at play include both the extrinsic and intrinsic apoptosis pathways, which means they are working from multiple angles to combat cancer. Additionally, these compounds also activate autophagy, a process that helps clear out damaged cells and contributes to the overall effectiveness of the treatment.
In summary, our findings suggest that these selenium-based compounds could be valuable candidates for future breast cancer therapies, worth considering in the ongoing fight against this disease.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
6
Boost immune system
55 people found this helpful
RM-10 is invaluable for those with serious health issues like cancer or MS. For someone with stage 3 or 4 breast cancer, I recommend taking 10 to 20 pills three times daily to bolster the immune system against cancer and chemotherapy. Following an alkaline diet and consuming RM-10, I am now five years in remission. It’s crucial to stay healthy with the right combination of diet, RM-10, and probiotics.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Raman S, Kasirajan S, Chinnapandi B, Karthikeyan K, Pandian A, et al. Luminescent Biogenic Selenium Nanoparticles From Indigofera aspalathoides Vahl ex DC: A Novel Hepatoprotective Strategy for Enhancing Live Health. Luminescence. 2025;40:e70101. 10.1002/bio.70101
- Yassein AS, Elamary RB, Alwaleed EA. Biogenesis, characterization, and applications of Spirulina selenium nanoparticles. Microb Cell Fact. 2025;24:39. 10.1186/s12934-025-02656-6
- Guo K, Yang X, Wang J, Chang W, Liu S, et al. Synthesis and Bioactivity of Selenium Nanoparticles From Tussilago farfara L. Polysaccharides: Antioxidant Properties and MCF-7 Cell Inhibition. Chem Biodivers. 2025. 10.1002/cbdv.202402677
- Zhang Q, Ali T, Ponnamperumage TNF, Lin Z, Setu NI, et al. A Photoinducible DNA Cross-Linking Agent with Potent Cytotoxicity and Selectivity Toward Triple-Negative Breast Cancer Cell Line. Chem Res Toxicol. 2025;38:216. 10.1021/acs.chemrestox.4c00499
- Sidira D, Siafaka A, Chrysikos D, Papadopoulos G, Stratopoulos E, et al. Selenium and Triple Negative Breast Cancer. Acta Med Acad. 2024;53:155. 10.5644/ama2006-124.450
- Zhang W, Wang Y, Gu M, Mao Z, Guan Y, et al. Manganese nanosheets loaded with selenium and gemcitabine activate the tumor microenvironment to enhance anti-tumor immunity. J Colloid Interface Sci. 2025;682:556. 10.1016/j.jcis.2024.11.224
- Pal N, Banerjee K, Sarkar S, Mandal TK, Bhabak KP. Synthesis of Thiazolidinedione- and Triazole-Linked Organoselenocyanates and Evaluation of Anticancer Activities Against Breast Cancer with Mechanistic Investigations. Chemistry. 2025;31:e202403026. 10.1002/chem.202403026
- Ali BA, Allam RM, Hasanin MS, Hassabo AA. Biosynthesis of selenium nanoparticles as a potential therapeutic agent in breast cancer: G2/M arrest and apoptosis induction. Toxicol Rep. 2024;13:101792. 10.1016/j.toxrep.2024.101792
- Qaed E, Liu W, Almoiliqy M, Mohamed R, Tang Z. Unleashing the potential of Genistein and its derivatives as effective therapeutic agents for breast cancer treatment. Naunyn Schmiedebergs Arch Pharmacol. 2024. 10.1007/s00210-024-03579-6
- Adibifar A, Salimi M, Rostamkhani N, Karami Z, Agh-Atabay AH, et al. Folic acid-conjugated bovine serum albumin-coated selenium-ZIF-8 core/shell nanoparticles for dual target-specific drug delivery in breast cancer. Drug Deliv Transl Res. 2024. 10.1007/s13346-024-01714-7
- Radomska D, Czarnomysy R, Marciniec K, Nowakowska J, Domínguez-Álvarez E, et al. Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells. Int J Mol Sci. 2024;25. 10.3390/ijms25179732
- Xu M, Gao X, Yue L, Li J, Feng X, et al. Sensitivity of triple negative breast cancer cells to ATM-dependent ferroptosis induced by sodium selenite. Exp Cell Res. 2024;442:114222. 10.1016/j.yexcr.2024.114222
- Ferro C, Matos AI, Serpico L, Fontana F, Chiaro J, et al. Selenium Nanoparticles Synergize with a KRAS Nanovaccine against Breast Cancer. Adv Healthc Mater. 2025;14:e2401523. 10.1002/adhm.202401523
- Li Y, Liu M, Kong B, Zhang G, Zhang Q. The role of selenium intervention in gut microbiota homeostasis and gene function in mice with breast cancer on a high-fat diet. Front Microbiol. 2024;15:1439652. 10.3389/fmicb.2024.1439652
- Radomska D, Czarnomysy R, Szymanowska A, Radomski D, Chalecka M, et al. Di- and Triselenoesters-Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer. Int J Mol Sci. 2024;25. 10.3390/ijms25147764
- Saad S, Abdelghany AM, Abou-ElWafa GS, Aldesuquy HS, Eltanahy E. Bioactivity of selenium nanoparticles biosynthesized by crude phycocyanin extract of Leptolyngbya sp. SSI24 cultivated on recycled filter cake wastes from sugar-industry. Microb Cell Fact. 2024;23:211. 10.1186/s12934-024-02482-2
- Wang Y, Du Z, Du H, Zhao J, Duan Y, et al. Associations between dietary intake of zinc and selenium and breast cancer: findings from a NHANES cross-sectional study. Chin Clin Oncol. 2025;14:2. 10.21037/cco-24-83
- Szwiec M, Tomiczek-Szwiec J, Marciniak W, Derkacz R, Huzarski T, et al. The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patient Receiving Neoadjuvant Chemotherapy. Cancers (Basel). 2025;17. 10.3390/cancers17050839
- Masuda Y, Yamashita S, Nakayama Y, Shimizu R, Konishi M. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Biol Pharm Bull. 2024;47:840. 10.1248/bpb.b23-00802
- Li X, Ruan Q, Yang W, Tian H, Wu N, et al. Polysaccharide isolated from eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses. Int J Biol Sci. 2024;20:664. 10.7150/ijbs.85276
- Alonso EN, Ferronato MJ, Fermento ME, Gandini NA, Romero AL, et al. Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells. Oncotarget. 2018;9:23396. 10.18632/oncotarget.25174
- Zhang Y, Sun D, Meng Q, Guo W, Chen Q, et al. Grifola frondosa polysaccharides induce breast cancer cell apoptosis via the mitochondrial-dependent apoptotic pathway. Int J Mol Med. 2017;40:1089. 10.3892/ijmm.2017.3081
- Alonso EN, Ferronato MJ, Gandini NA, Fermento ME, Obiol DJ, et al. Antitumoral Effects of D-Fraction from Grifola Frondosa (Maitake) Mushroom in Breast Cancer. Nutr Cancer. 2017;69:29. 10.1080/01635581.2017.1247891
- Roldan-Deamicis A, Alonso E, Brie B, Braico DA, Balogh GA. Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALBc mice. Cancer Med. 2016;5:2427. 10.1002/cam4.744
- Alonso EN, Orozco M, Eloy Nieto A, Balogh GA. Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. J Med Food. 2013;16:602. 10.1089/jmf.2012.0222
- Soares R, Meireles M, Rocha A, Pirraco A, Obiol D, et al. Maitake (D fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation. J Med Food. 2011;14:563. 10.1089/jmf.2010.0095
- Deng G, Lin H, Seidman A, Fornier M, D'Andrea G, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol. 2009;135:1215. 10.1007/s00432-009-0562-z
- Kodama N, Komuta K, Nanba H. Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J Med Food. 2003;6:371.
- Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer patients?. Altern Med Rev. 2002;7:236.
- Roberts KE, Adsett IT, Rickett K, Conroy SM, Chatfield MD, et al. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022;1:CD013167. 10.1002/14651858.CD013167.pub2
- Santos KF, Gutierres JM, Pillat MM, Rissi VB, Santos Araújo MD, et al. Uncaria tomentosa extract alters the catabolism of adenine nucleotides and expression of ecto-5'-nucleotidase/CD73 and P2X7 and A1 receptors in the MDA-MB-231 cell line. J Ethnopharmacol. 2016;194:108. 10.1016/j.jep.2016.08.051
- Riva L, Coradini D, Di Fronzo G, De Feo V, De Tommasi N, et al. The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line. Anticancer Res. 2001;21:2457.
